from The American Heritage® Dictionary of the English Language, 4th Edition
- n. A nucleoside formed by the deamination of adenosine or the hydrolysis of inosinic acid.
from Wiktionary, Creative Commons Attribution/Share-Alike License
- n. Any nucleoside formed from hypoxanthine attached to a ribose
from the GNU version of the Collaborative International Dictionary of English
- n. A ribonucleoside (C10H12N4O5) found in meat and meat extracts, differing from adenosine in having a hydroxyl rather than an amine attached to the purine ring. It may be prepared from adenosine by the enzyme adenosine deaminase, or by chemical deamination, as with nitrous acid. It participates in some cellular functions, but is not one of the normal nucleoside components of RNA.
from WordNet 3.0 Copyright 2006 by Princeton University. All rights reserved.
- n. a nucleoside that is formed by the deamination of adenosine; used in kidney transplantation to provide a temporary source of sugar
Compared to human milk, cow's milk has lower levels of nucleotide as uridine, inosine, and cytidine.
Basically, there are three major chemicals that the tongue detects as being flavorful: inosine monophosphate (IMP), guanine monophosphate (GMP), and glutamate.
When a cell extracts energy from ATP, it is transformed into a series of smaller molecules, one of which, IMP inosine monophosphate, has a savory taste similar to that of glutamate.
They break proteins into savory amino acids; glycogen into sweet glucose; the energy currency ATP into savory IMP inosine monophosphate; fats and fat-like membrane molecules into aromatic fatty acids.
Previous studies had identified the genetic variants as the cause of a deficiency in the production of an enzyme, inosine triphosphatase.
We have observed that although the serum UA levels increased significantly during the inosine treatment phase of the trial, from 4. 2±0.8 to 7. 1±1.7 ml, blood pressure remained unchanged, averaging 123±15
Both parameters were recorded throughout the trial that included 69 visits by patients at baseline and during the placebo phase as well as 138 visits while receiving inosine treatment.
Recently we conducted a clinical trial to determine whether raising the serum UA levels through the oral administration of inosine is well tolerated and may benefit patients with multiple sclerosis.
NOV-205 is an injectable, small-molecule proprietary formulation of oxidized glutathione and inosine that acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties.
Mycophenolic acid (MPA) is a selective inhibitor of inosine